Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reltecimod in sepsis-associated acute kidney injury
2018-002547-29Phase 2Completed
- Sponsor
- Atox Bio
- Start
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sepsis-associated acute kidney injury (S-AKI), sepsis and Intra-abdominal infection (IAI) comparing Reltecimod + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Complete recovery at Day 14. Started Oct 2018; status: completed.
02
Drugs
reltecimod
03
Conditions
sepsis-associated acute kidney injury (S-AKI)sepsisIntra-abdominal infection (IAI)
Beyond the preview
Go deeper on 2018-002547-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002547-29.